Haemonetics Corporation updated revenue guidance for the fiscal year 2024. For the year, the company expects GAAP total reported revenue growth to be between 10% to 12% against previous guidance of total reported revenue growth to be between 8% to 10% and total organic revenue growth to be between 10% to 12% against previous guidance of total organic revenue growth to be between 8% to 10%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.4 USD | -0.22% |
|
-0.62% | -0.13% |
06-12 | Haemonetics Shares Rise After Upgrade From Needham | MT |
06-12 | Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.13% | 4.35B | |
-3.19% | 105B | |
-4.14% | 67.55B | |
+15.49% | 46.71B | |
-6.00% | 46.39B | |
+4.82% | 40.93B | |
+22.10% | 31.63B | |
+12.18% | 24.28B | |
-8.53% | 23.46B | |
-12.33% | 21.95B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024